Inhibition of the angiotensin II type 2 receptor AT 2 R is a novel therapeutic strategy for glioblastoma

Autor: Richard Perryman, Alexander Renziehausen, Hamidreza Shaye, Androniki D. Kostagianni, Antonis D. Tsiailanis, Thomas Thorne, Maria V. Chatziathanasiadou, Gregory B. Sivolapenko, Mohamed Ahmed El Mubarak, Gye Won Han, Barbara Zarzycka, Vsevolod Katritch, Guillaume Lebon, Cristiana Lo Nigro, Laura Lattanzio, Sophie V. Morse, James J. Choi, Kevin O’Neill, Zoi Kanaki, Apostolos Klinakis, Tim Crook, Vadim Cherezov, Andreas G. Tzakos, Nelofer Syed

Publikováno v: Perryman, R, Renziehausen, A, Shaye, H, Kostagianni, A D, Tsiailanis, A D, Thorne, T, Chatziathanasiadou, M V, Sivolapenko, G B, El Mubarak, M A, Han, G W, Zarzycka, B, Katritch, V, Lebon, G, Lo Nigro, C, Lattanzio, L, Morse, S V, Choi, J J, O'Neill, K, Kanaki, Z, Klinakis, A, Crook, T, Cherezov, V, Tzakos, A G & Syed, N 2022, ' Inhibition of the angiotensin II type 2 receptor AT2R is a novel therapeutic strategy for glioblastoma ', Proceedings of the National Academy of Sciences of the United States of America, vol. 119, no. 32, e2116289119, pp. 1-12 . https://doi.org/10.1073/pnas.2116289119
Proceedings of the National Academy of Sciences of the United States of America, 119(32):e2116289119, 1-12. National Acad Sciences

Glioblastoma (GBM) is an aggressive malignant primary brain tumor with limited therapeutic options. We show that the angiotensin II (AngII) type 2 receptor (AT 2 R) is a therapeutic target for GBM and that AngII, endogenously produced in GBM cells, p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddb8607c8cd496659695f1c6f70be1f3
https://doi.org/10.1073/pnas.2116289119